ABVC BioPharma Closes $3.39 Million Convertible Note Offering to Fund Operations and Settle Lind Claim

ABVC BioPharma's $3.39 million private placement of senior convertible notes provides working capital and settles a $625,000 claim with Lind Global Fund II, supporting its subsidiary-based development strategy.

Houston Metrowire Staff
••Business
ABVC BioPharma Closes $3.39 Million Convertible Note Offering to Fund Operations and Settle Lind Claim

ABVC BioPharma, Inc. (NASDAQ: ABVC) has closed a private placement of original issue discount senior convertible promissory notes with institutional and other accredited investors, raising gross proceeds of approximately $3.39 million before placement agent fees and offering expenses. The financing matters because it addresses both immediate liquidity and a lingering legal obligation, giving the clinical-stage biopharmaceutical company room to advance its drug and device portfolio while restructuring its balance sheet.

The 17.5% OID notes carry an aggregate principal amount of $4,106,060 and mature on June 30, 2027. They become convertible eight months after issuance into common stock at a price equal to 85% of the average of the three volume-weighted average prices for the three trading days immediately prior to conversion, subject to a floor price and adjustments. That structure means the notes could dilute existing shareholders if converted, a tradeoff the company accepted to secure capital without immediate equity pricing. The company disclosed the transaction through www.newmediawire.com.

ABVC expects to use net proceeds for general working capital, funding of its subsidiaries, and a $625,000 settlement payment to Lind Global Fund II LP under a definitive release and settlement agreement. That payment is expected to satisfy specified outstanding claims and support the company's ability to pursue broader financing and business development initiatives. Resolving the Lind matter removes a potential distraction and may improve ABVC's standing with future investors and partners.

The offering also underpins ABVC's strategy of advancing its pharmaceutical and medical-device portfolio through strategic licensing, subsidiary development, and independent financing. The company has established dedicated platforms across its principal development areas: AiBtl BioPharma Inc. for central nervous system drug programs, OncoX BioPharma for oncology, ForSeeCon Eye for ophthalmic medical-device development and commercialization, and BioKey (Cayman), Inc. for contract pharmaceutical development and manufacturing services as well as an AI biotechnology innovation platform. Through these arrangements, ABVC seeks to advance development programs while creating opportunities for licensing revenues, milestone payments, future royalties, and equity value, and it continues to evaluate strategic financing and capital-market opportunities for its affiliated businesses.

WallachBeth Capital, Inc. acted as placement agent. Hunter Taubman Fischer & Li LLC served as legal counsel to the company, while Sichenzia Ross Ference Carmel LLP advised the placement agent. The notes and underlying shares are not registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption. Additional details will appear in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission.

Blockchain Registration

QR Code for Blockchain Registration